These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
17. Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation. Marzi A; Menicucci AR; Engelmann F; Callison J; Horne EJ; Feldmann F; Jankeel A; Feldmann H; Messaoudi I Front Immunol; 2018; 9():3071. PubMed ID: 30723475 [TBL] [Abstract][Full Text] [Related]
18. Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques. Marzi A; Fletcher P; Feldmann F; Saturday G; Hanley PW; Feldmann H Lancet Microbe; 2023 Mar; 4(3):e171-e178. PubMed ID: 36739878 [TBL] [Abstract][Full Text] [Related]
19. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Daddario-DiCaprio KM; Geisbert TW; Ströher U; Geisbert JB; Grolla A; Fritz EA; Fernando L; Kagan E; Jahrling PB; Hensley LE; Jones SM; Feldmann H Lancet; 2006 Apr; 367(9520):1399-404. PubMed ID: 16650649 [TBL] [Abstract][Full Text] [Related]
20. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. Geisbert TW; Daddario-DiCaprio KM; Williams KJ; Geisbert JB; Leung A; Feldmann F; Hensley LE; Feldmann H; Jones SM J Virol; 2008 Jun; 82(11):5664-8. PubMed ID: 18385248 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]